But AtheroGenics claims that the trial actually shows a statistically significant benefit in preventing the combination of heart attack, stroke and death.
Many researchers, however, point out that the 30-day stroke and death rate in stent patients was significantly higher (4.8%) than that of surgery patients (2.6%).